Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

YTS 104

Next Previous
Drug Profile

YTS 104

Alternative Names: Anti-LILRB4 T-cell therapy - Beijing Qingyi Taike Pharmaceutical Technology; YTS-104

Latest Information Update: 24 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator China Immunotech
  • Developer Beijing Qingyi Taike Pharmaceutical Technology; China Immunotech; Hebei Yanda Lu Daopei Hospital
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Myeloid leukaemia
  • Preclinical Solid tumours

Most Recent Events

  • 07 Dec 2024 Efficacy and adverse event data from a phase I trial in Acute myeloid leukaemia presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
  • 03 Aug 2024 Beijing Qingyi Taike Pharmaceutical Technology completes a phase I trial in Myeloid leukaemia and Acute myeloid leukaemia (Second-line therapy or greater) in China (IV) (NCT05548088)
  • 15 Jun 2023 China Immunotech plans a phase I trial for Multiple myeloma (Second-line therapy or greater) in China (IV) (NCT05913804)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top